Personalis, Inc. (PSNL) Cash Flow Statement

The OCF/NI ratio has been volatile, swinging from 1.57 in Q1 2024 to 0.16 in Q3 2024, and recently settling near 0.8, suggesting that non-cash charges like SBC and D&A are not fully offsetting working capital outflows. The widening gap between net income and operating cash flow in recent quarters implies that accruals are becoming a larger drag, potentially reflecting delayed collections or inventory build-up. Investors should monitor whether this trend persists, as it may signal weakening earnings quality.

The FCF trajectory is sharply negative, with the burn rate more than doubling over the past two years, even as revenue showed a sequential uptick in Q2 2026. This suggests that the company is investing heavily in growth, but the cash returns are not yet materializing, possibly due to the high fixed-cost structure and the lag between clinical volume growth and revenue recognition. The negative FCF margin, which is far worse than peers like GH and TWST, underscores the urgency of achieving scale to reverse this trend.

The low absolute CapEx, particularly in recent quarters (e.g., $77K in Q5 2025), appears inconsistent with the company's stated need for high-throughput sequencing infrastructure. This may indicate that the company is leasing equipment or relying on third-party capacity, which would shift costs from CapEx to operating expenses, potentially understating true capital intensity. The spike in CapEx/Revenue in Q1 2026, though, suggests some investment in capacity, but the overall trend is one of minimal direct capital expenditure, which may limit the company's ability to scale without additional financing.

The erratic working capital changes, ranging from -$8.0M to +$3.9M, highlight the lumpy nature of the company's revenue and collections, likely tied to the timing of large biopharma contracts and the VA program. Positive working capital contributions in some quarters (e.g., Q4 2024) suggest efficient collections or delayed payables, but the negative swings in others (e.g., Q1 2025) indicate cash outflows for inventory or receivables. This volatility complicates cash flow forecasting and may require a larger cash buffer to manage operational needs.

The absence of any shareholder returns is consistent with a company in a high-growth, cash-burning phase, where every dollar is needed to fund operations and R&D. The only acquisition activity was a small $120K outflow in Q1 2026, suggesting that management is not pursuing inorganic growth. This capital deployment strategy is typical for pre-profit diagnostics companies, but it also means that investors are entirely reliant on future operational success to generate returns, increasing the risk of dilution if the cash runway shortens.

The cumulative gap between net income and operating cash flow suggests that non-cash charges, such as SBC and D&A, have been significant, totaling roughly $25M per year. This divergence implies that the company's cash burn is less severe than its accounting losses, but the trend is still deeply negative. The positive divergence may also reflect favorable working capital timing, but given the recent acceleration in cash burn, investors should not rely on this gap to persist. The cumulative cash consumption of over $168M underscores the need for either a dramatic improvement in operating performance or additional capital raises.